Correction: BTX didn't 'steal' Nat Ricciardi, he spent nearly 40 years with Pfizer before retiring. Great pick up for AST's board no doubt.
LifeMap already has the largest researcher based genetic/stemcell database, an upgrade early next year should keep them at the forefront.
Stem Cell News today:
In a boon to stem cell research and regenerative medicine, scientists at Boston Children's Hospital, the Wyss Institute for Biologically Inspired Engineering at Harvard University and Boston University have created a computer algorithm called CellNet as a "roadmap" for cell and tissue engineering, to ensure that cells engineered in the lab have the same favorable properties as cells in our own bodies. CellNet and its application to stem cell engineering are described in two back-to-back papers in the August 14 issue of the journal Cell.
Scientists around the world are engaged in culturing pluripotent stem cells (capable of forming all the body's tissues) and transforming them into specialized cell types for use in research and regenerative medicine. Available as an Internet resource for any scientist to use, CellNet provides a much needed "quality assurance" measure for this work.
Little by little coming out from under the radar. Cancer diagnostic products out early next year! Buy now before Wall St and Cramer start!
PanCDX products will start to come to market at that time. Current status quo breast cancer diagnostics are archaic, Biotime will help change this.
And at $2.56. Buy of a life time.
BioTime, Inc. (NYSE MKT: BTX) and its subsidiary OncoCyte Corporation today announced that OncoCyte has expanded the clinical development of its urine-based bladder cancer diagnostic test by initiating a multi-site clinical trial. The trial, which will involve up to 1,200 patient samples obtained from at least four large urology clinics located throughout the United States, has received Institutional Review Board (IRB) approval at multiple sites and should begin enrolling patients within the next week. OncoCyte’s initial clinical study of its bladder cancer diagnostic test began in January and involves pathology specimens being collected at a leading medical institution with an international reputation for excellence and discovery. The multi-site clinical trial, which has been initiated in part due to positive interim data from the ongoing study in pathology specimens, is designed to expand the potential use of the PanC-Dx™ bladder cancer test beyond pathology laboratories and into urologic practices at the point of cystoscopy. Cystoscopy along with urine cytopathology, are the standard methods utilized for bladder cancer screening and diagnosis. The multi-site clinical trial should be completed within 12 months.
long term hold but their two products look to have a very good chance in a future billion dollar cancer and spine regen markets. Good news today, A) both clinical trials will likely be fully paid for, and B) opc1 phase two will most definitely have FDA fast track and phase two trials start by years end.
Just a matter of time
All systems go! Main gist of webcast:
-FDA Fast track eligibility for opc-1
-Additional eligibility for $25 MIL CIRM opc-1 phase 3 trial
-Dendritic cancer vaccine will have have up tp 20 MIL in clinical trial costs paid for by a charitable health organization.
All good in AST land
Main message is that AST has their trials paid for. Got 13 MIL from CIRM in May, for opc-1, and eligible for additional 25 MIL CIRM grant for phase 3 plus fast track status.
Dendritic cancer vaccine will have have up tp 20 MIL in clinical trial costs paid for by working a deal with a charitable health organization.
1-Next week marks the beginning of numerous milestone announcements including restart of spine trials.
2-BTX in R&D/building phase for last seven years and finally about to announce multiple clinical trials
3-Two low hanging fruit products with very short clinical trials will be breast cancer diagnostic blood test product PanC-DX, the other being cosmetic regen product Renevia which uses ECM and adipose cells.
4-BTX currently pulling out of a 5 yr low!
5-Currenly holds most stem cell patents for one single company worldwide
6-Balanced approach, with growing research products and many regen therapeutics on the way
7-A+ biz plan with 7 subsidiaries, no debt, world renowned CEO's & scientific leaders
8-Building best in class corporate/institutional partners including, CIRM, TEVA, Weill Cornell, Wistar Institute, Mt Sini, Spain Stem Cell Center, Millipore and more to be announced in coming weeks.
9-Owns worlds most popular online genetic database company LifeMaps which is currently developing next gen personalized medicine app along with Mt Sini Memorial genetic dept.
10-Recently IPO'ed first subsidiary Astrias, next year likely to see two more; OrthoCyte(cartilage.bone, & tendon regen), ReCyte(heart, blood & vascular regen).
11-Ok, one more reason......totally mind blowing....Next year Biotime will discuss pre-clinical results of a total revolutionary technology that will change the world as we know it. Our CEO Dr. Michael West culmination of a lifetime of knowledge and passion in the field of Gerontology will come to light. Yes, that's right, I'm talking about life extension regen therapy.
These are very exciting times and look forward to Biotimes progression into becoming a next generation biotech giant. Hope some have found this info useful.
Some of these patents are key for subsidiary ReCyte. New company merger for ReCyte this October!
Take a look at the 5 yr chart and know that Biotime will have two HUGE products on the market within 6 months. A)Best in class cancer diagnostics product PanC-DX, and B) cosmetic surgery product Renevia.
Both of these products are cutting edge and industry game changers. Also both products are partnered with top institutions/hospitals; Weill Cornell for PanC-DX and for Renevis the Spain Stem Cell Center which is one of largest cosmetic surgery center in EU.
Game changers because they are next generation, meaning that they will REPLACE the current methods of practice. PanC-DX will be a simple blood test and will be crossed checked with the latest genetic markers replacing radioactive mammograms that are often a shot in the dark in terms of detecting malignant early formations. And Biotimes cosmetic surgery product Renevia will use an extra-cellular matrix along with a patients own adipose(fat) stem cells replacing the use of silicone.
Dr West is a true pioneer, medical app's are the future of healthcare. LifeMPs will might make a tremendous IPO in a year or two!
Crossing my fingers, but then again feel secure knowing two of the leading scientists in this field are on the same page!
For those not following trends within the industry.....over the last year the race to reprogram the stem cell has moved from IPS cell to SCNT(therapeutic cloning). Most scientists now know that reprogramming autologous(IPS cells) is more complicated then once thought. No magic bullet, and will instead take years to perfect as scientists dig deeper and deeper into such complexities.
The 'cloning' .....and for that matter embryonic stem cell stigma of the past is fading and the urgency of finding cures to disease has superceded the fears of such technologies. Recently Dr. West of Biotime hit the nail on the head when he compared the fear of hESC's to Harvard's ban of recombinant DNA in the 1970's.
Robert Lanza's patents over the last 3 years reflect this trend in the scientific community and it's refocus on therapeutic cloning. Although not perfected the SCNT method looks to be the simplest way to perfect reprogramming hESC's into histocompatible cells/tissues for transplant.
Here are 5 of Lanza's SCNT patents over the last few years:
-11/07/13 - 20130295056 - Generation of histocompatible tissues using nuclear transplantation
-08/02/12 - 20120196769 - Methods of repairing tandemly repeated dna sequences and extending cell life-span using nuclear transfer
-09/27/12 - 20120246746 - Method for generating immune-compatible cells and tissues using nuclear transfer techniques
-07/19/12 - 20120184035 - Methods and compositions for reprogramming cells
-11/03/11 - 20110268709 - Generation of histocompatible tissues using nuclear transplantation
Happy Independence Day!
And to add...yes LP can sell at any time, but the point is they took a 30 ML dollar chance. Yes short term upside is predictable here but also med and long term looking better after ACTC settled lawsuit and finally hiring a CEO.